CIK 0000906709
- Non-accelerated filer
- Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 943134940
- Phone
- +1 415-482-5300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- 4/A Grant or award Director acquired 9,100 shares (grant or award)
- 4/A Grant or award Director acquired 9,100 shares (grant or award)
- 4/A Grant or award Director acquired 9,100 shares (grant or award)
- 4/A Grant or award Director acquired 9,100 shares (grant or award)
- 4/A Grant or award Director acquired 9,100 shares (grant or award)
- 4/A Grant or award Director acquired 9,100 shares (grant or award)
- 4/A Grant or award Director acquired 9,100 shares (grant or award)
- 4 Grant or award Director acquired 9,100 shares (grant or award)
- 4 Grant or award Director acquired 9,100 shares (grant or award)
- 4 Grant or award Director acquired 9,100 shares (grant or award)
- 4 Grant or award Director acquired 9,100 shares (grant or award)
- 4 Grant or award Director acquired 9,100 shares (grant or award)
- 4 Grant or award Director acquired 9,100 shares (grant or award)
- 4 Grant or award Director acquired 9,100 shares (grant or award)
- 4 Open-market sale SVP, COO & CFO sold 2,000 shares at $19.96 ($39,920)
- 4 Open-market sale Director sold 2,250 shares at $19.74 ($44,415)
- 4 Open-market sale Director sold 8,000 shares at $18.53 ($148,240)
- 4 Exercise or conversion Director acquired 30,000 shares (option exercise)
- 4 Open-market sale Chief R&D Officer sold 26,200 shares at $19.67 ($515,354)
- 4 Open-market sale SVP & General Counsel sold 1,529 shares at $19.67 ($30,075)
Page 11 of 49 · 970 filings